Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6192)	12/28/1998 1:38:00 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 9719

CEGE noted in the most recent 10q filing that they were notified of an interference proceeding concerning the gene activation technology. The company has not returned my calls concerning the matter. I noticed last week that there was a granted US patent on this technology to an individual that apparently was not obviously affiliated with any company (Scott C. Chappel, US5272071, granted 12/1993, Method for the modification of the expression characteristics of an endogenous gene of a given cell line). That patent was originally for the purpose of generating FSH. The CEGE patent uses YACS and apparently is performed in vivo. Chappel's patent is for use in cell lines. It would seem to me that any production of EPO would be done via cell line expression and subsequent purification. Or, is the technology you cite soley for gene therapy purposes?